PT3576740T - Tratamento de cancro - Google Patents

Tratamento de cancro

Info

Publication number
PT3576740T
PT3576740T PT187022991T PT18702299T PT3576740T PT 3576740 T PT3576740 T PT 3576740T PT 187022991 T PT187022991 T PT 187022991T PT 18702299 T PT18702299 T PT 18702299T PT 3576740 T PT3576740 T PT 3576740T
Authority
PT
Portugal
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
PT187022991T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3576740T publication Critical patent/PT3576740T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
PT187022991T 2017-12-20 2018-02-02 Tratamento de cancro PT3576740T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20

Publications (1)

Publication Number Publication Date
PT3576740T true PT3576740T (pt) 2023-08-18

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187022991T PT3576740T (pt) 2017-12-20 2018-02-02 Tratamento de cancro

Country Status (5)

Country Link
EA (1) EA201991818A1 (zh)
MA (1) MA47408B1 (zh)
PT (1) PT3576740T (zh)
TW (1) TWI798199B (zh)
WO (1) WO2018141921A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501355A (ja) * 2018-09-21 2022-01-06 ヤンセン ファーマシューティカ エヌ．ベー． 胆管癌の処置
JP2022515197A (ja) * 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
EP3923942A1 (en) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Cancer treatment
US20220202703A1 (en) * 2019-03-15 2022-06-30 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
JOP20210260A1 (ar) * 2019-03-29 2023-01-30 Janssen Pharmaceutica Nv مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية
US20220233537A1 (en) * 2019-05-31 2022-07-28 Qed Therapeutics, Inc. Methods of treating urinary system cancers
CA3176713A1 (en) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
AU2021220285A1 (en) * 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين

Also Published As

Publication number Publication date
EA201991818A1 (ru) 2020-02-05
WO2018141921A1 (en) 2018-08-09
MA47408A (fr) 2019-12-11
TW201839399A (zh) 2018-11-01
TWI798199B (zh) 2023-04-11
MA47408B1 (fr) 2023-08-31

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
LT3580211T (lt) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidai, skirti vėžio gydymui
IL259996A (en) Combinations for cancer treatment
IL263802A (en) Combinations of cancer treatments
HK1258319A1 (zh) 癌症療法
PT3576740T (pt) Tratamento de cancro
IL263123A (en) Cancer treatments
HK1231561A1 (zh) 癌症治療
GB201706451D0 (en) Cancer treatment
IL268463A (en) Cancer treatment
HK1251794A1 (zh) 癌症治療
IL274626A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
GB201704909D0 (en) Cancer therapy
GB201819920D0 (en) Cancer treatment
GB201711855D0 (en) Cancer therapy
GB201522433D0 (en) Cancer treatment
GB201713852D0 (en) Cancer treatment
GB201811431D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
GB201720533D0 (en) Cancer treatments
GB201711250D0 (en) Cancer therapy
GB201718806D0 (en) Breast cancer treatment
GB201710198D0 (en) Cancer therapy